Chemotherapy-Free Combo Improves Survival in Metastatic Colorectal Cancer

By News Health
5 hours Ago

(MedPage Today) — BERLIN — The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly improved overall survival (OS) among previously treated patients with metastatic colorectal cancer, a phase…

Source link : https://www.medpagetoday.com/meetingcoverage/esmo/118047

Author :

Publish date : 2025-10-20 21:11:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Physician Exits From Medicare Increased in Vulnerable Areas

Cancer Study Links COVID Shots to Longer Survival

Adverse Event Risks Vary Among Asthma Biologics, FDA Data Show

Global Study Reports Rise in Several Cancers Among Adults of All Ages

Primary Care Docs Spend This Many Hours Per Week Caring for Patients

Who Knew? Autoimmunity Might Actually Benefit Some Cancer Patients